DE60132170D1 - Modulierung der durch cpg-oligonukleotide verursachte immunstimulierung durch positionsbedingte veränderung von nukleosiden - Google Patents
Modulierung der durch cpg-oligonukleotide verursachte immunstimulierung durch positionsbedingte veränderung von nukleosidenInfo
- Publication number
- DE60132170D1 DE60132170D1 DE60132170T DE60132170T DE60132170D1 DE 60132170 D1 DE60132170 D1 DE 60132170D1 DE 60132170 T DE60132170 T DE 60132170T DE 60132170 T DE60132170 T DE 60132170T DE 60132170 D1 DE60132170 D1 DE 60132170D1
- Authority
- DE
- Germany
- Prior art keywords
- nucleosides
- modulation
- changing
- cpg oligonucleotides
- caused
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
- C12N2310/3125—Methylphosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/319—Chemical structure of the backbone linked by 2'-5' linkages, i.e. having a free 3'-position
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17856200P | 2000-01-26 | 2000-01-26 | |
US178562P | 2000-01-26 | ||
PCT/US2001/002681 WO2001055370A2 (en) | 2000-01-26 | 2001-01-26 | MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60132170D1 true DE60132170D1 (de) | 2008-02-14 |
DE60132170T2 DE60132170T2 (de) | 2008-12-18 |
Family
ID=22653030
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60132170T Expired - Lifetime DE60132170T2 (de) | 2000-01-26 | 2001-01-26 | MODULIERUNG DER DURCH CpG-OLIGONUKLEOTIDE VERURSACHTEN IMMUNSTIMULIERUNG DURCH POSITIONSBEDINGTE VERÄNDERUNG VON NUKLEOSIDEN |
Country Status (8)
Country | Link |
---|---|
US (2) | US6815429B2 (de) |
EP (1) | EP1252307B1 (de) |
JP (2) | JP4443810B2 (de) |
AT (1) | ATE382690T1 (de) |
AU (1) | AU783687B2 (de) |
CA (1) | CA2398432C (de) |
DE (1) | DE60132170T2 (de) |
WO (1) | WO2001055370A2 (de) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7935675B1 (en) * | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
AU2001294750C1 (en) * | 2000-09-26 | 2008-09-18 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
US7785610B2 (en) * | 2001-06-21 | 2010-08-31 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same—III |
DK2423335T3 (da) | 2001-06-21 | 2014-08-18 | Dynavax Tech Corp | Kimæriske immunmodulatoriske forbindelser og fremgangsmåder til anvendelse deraf |
EP1420829A4 (de) | 2001-08-07 | 2006-05-17 | Dynavax Tech Corp | Immunmodulierende zusammensetzungen, formulierungen sowie verfahren zu deren verwendung |
IL160157A0 (en) | 2001-08-17 | 2004-07-25 | Coley Pharm Group Inc | Combination motif immune stimulation oligonucleotides with improved activity |
US7276489B2 (en) | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
CA2388049A1 (en) | 2002-05-30 | 2003-11-30 | Immunotech S.A. | Immunostimulatory oligonucleotides and uses thereof |
AR040996A1 (es) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
EP1578954A4 (de) | 2002-12-11 | 2010-08-11 | Coley Pharm Group Inc | 5'-cpg-nukleinsäuren und verwendungsverfahren |
SG2011035342A (en) | 2002-12-23 | 2016-12-29 | Dynavax Tech Corp | Immunostimulatory sequence oligonucleotides and methods of using the same |
US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
AU2004206820B2 (en) | 2003-01-16 | 2010-06-10 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides |
US7354907B2 (en) | 2003-02-07 | 2008-04-08 | Idera Pharmaceuticals, Inc. | Short immunomodulatory oligonucleotides |
JP4976848B2 (ja) | 2003-02-20 | 2012-07-18 | ユニバーシティー オブ コネティカット ヘルス センター | アルファ(2)マクログロブリン−抗原分子複合体を用いる癌および感染性疾患の治療のための方法および組成物 |
KR20060012622A (ko) | 2003-05-16 | 2006-02-08 | 하이브리돈, 인코포레이티드 | 화학요법제와 함께 이뮤노머를 사용하는 상승적 암 치료방법 |
WO2005009355A2 (en) | 2003-07-15 | 2005-02-03 | Hybridon, Inc. | Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy |
AU2004275876B2 (en) | 2003-09-25 | 2011-03-31 | Coley Pharmaceutical Gmbh | Nucleic acid-lipophilic conjugates |
SG123799A1 (en) | 2003-10-30 | 2006-07-26 | Coley Pharm Gmbh | C-class oligonucleotide analogs with enchanced immunostimulatory potency |
JP2007530449A (ja) | 2003-12-08 | 2007-11-01 | イデラ ファーマシューティカルズ インコーポレイテッド | 小オリゴヌクレオチドに基づく化合物による免疫刺激特性の調節 |
AU2005326144A1 (en) * | 2004-06-08 | 2006-08-03 | Coley Pharmaceutical Gmbh | Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist |
MY159370A (en) | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
CA2589406A1 (en) * | 2004-12-09 | 2006-06-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering rnas |
US8357665B2 (en) | 2005-10-12 | 2013-01-22 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
US7776834B2 (en) * | 2005-11-07 | 2010-08-17 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
US7470674B2 (en) | 2005-11-07 | 2008-12-30 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
JP5184366B2 (ja) | 2005-11-07 | 2013-04-17 | イデラ ファーマシューティカルズ インコーポレイテッド | 修飾された免疫刺激性ジヌクレオチドを含む、オリゴヌクレオチドに基づく化合物の免疫刺激特性 |
NZ575437A (en) | 2006-09-27 | 2012-02-24 | Coley Pharm Gmbh | Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity |
AU2009302468A1 (en) * | 2008-10-06 | 2010-04-15 | Idera Pharmaceuticals, Inc. | Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto |
JP5759445B2 (ja) | 2009-03-25 | 2015-08-05 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 病原体に対する哺乳類先天性免疫抵抗性の刺激のための組成物 |
MX340363B (es) | 2010-11-19 | 2016-07-06 | Idera Pharmaceuticals Inc | Compuestos de oligonucleotidos inmuno-reguladores (iro) que modulan la respuesta inmune basada en receptores tipo toll. |
US10202615B2 (en) | 2010-12-10 | 2019-02-12 | Vanderbilt University | Mammalian genes involved in toxicity and infection |
FR2975600B1 (fr) | 2011-05-24 | 2013-07-05 | Assist Publ Hopitaux De Paris | Agents pour le traitement de tumeurs |
US10286065B2 (en) | 2014-09-19 | 2019-05-14 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5149798A (en) | 1989-04-06 | 1992-09-22 | Worcester Foundation For Experimental Biology | Process for synthesizing oligonucleotides and their analogs adaptable to large scale syntheses |
US5532130A (en) | 1993-07-20 | 1996-07-02 | Dyad Pharmaceutical Corporation | Methods and compositions for sequence-specific hybridization of RNA by 2'-5' oligonucleotides |
US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
US5886165A (en) | 1996-09-24 | 1999-03-23 | Hybridon, Inc. | Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments |
US6426334B1 (en) | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
-
2001
- 2001-01-26 AU AU31193/01A patent/AU783687B2/en not_active Ceased
- 2001-01-26 CA CA2398432A patent/CA2398432C/en not_active Expired - Fee Related
- 2001-01-26 JP JP2001554399A patent/JP4443810B2/ja not_active Expired - Fee Related
- 2001-01-26 WO PCT/US2001/002681 patent/WO2001055370A2/en active IP Right Grant
- 2001-01-26 US US09/770,602 patent/US6815429B2/en not_active Expired - Fee Related
- 2001-01-26 AT AT01903365T patent/ATE382690T1/de not_active IP Right Cessation
- 2001-01-26 DE DE60132170T patent/DE60132170T2/de not_active Expired - Lifetime
- 2001-01-26 EP EP01903365A patent/EP1252307B1/de not_active Expired - Lifetime
-
2002
- 2002-12-09 US US10/314,647 patent/US7329648B2/en not_active Expired - Fee Related
-
2009
- 2009-08-03 JP JP2009180403A patent/JP2009292829A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2398432A1 (en) | 2001-08-02 |
WO2001055370A2 (en) | 2001-08-02 |
CA2398432C (en) | 2012-06-19 |
US20020055475A1 (en) | 2002-05-09 |
AU3119301A (en) | 2001-08-07 |
EP1252307B1 (de) | 2008-01-02 |
EP1252307A2 (de) | 2002-10-30 |
ATE382690T1 (de) | 2008-01-15 |
US20030186912A1 (en) | 2003-10-02 |
WO2001055370A3 (en) | 2002-01-17 |
US6815429B2 (en) | 2004-11-09 |
JP4443810B2 (ja) | 2010-03-31 |
US7329648B2 (en) | 2008-02-12 |
AU783687B2 (en) | 2005-11-24 |
WO2001055370A9 (en) | 2002-10-17 |
DE60132170T2 (de) | 2008-12-18 |
JP2003520811A (ja) | 2003-07-08 |
JP2009292829A (ja) | 2009-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60132170D1 (de) | Modulierung der durch cpg-oligonukleotide verursachte immunstimulierung durch positionsbedingte veränderung von nukleosiden | |
DE60109916D1 (de) | Modulation von oligonukleotid cpg-vermittelter immunstimulation durch modifikation der nucleoside | |
DE60017259D1 (de) | Modulierung der durch cpg-oligonukleotide verursachten immunstimulierung durch positionsbedingte veränderung von nukleosiden | |
PL375398A1 (en) | Immunostimulatory nucleic acids | |
EP1601789A4 (de) | Modulation derimmunstimulatorischen eigenschaften von verbindungen auf oligonucleotid-basisdurch verwendung modifizierter immunstimulatorischer dinucleotide | |
MXPA05013553A (es) | Pirrolodihidroisoquinolinas como inhibidores de pde10. | |
DK1117672T3 (da) | Antisense-modulation af survivin-ekpression | |
WO2002026757A3 (en) | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | |
EP2060269A3 (de) | Modulation der immunstimulatorischen Eigenschaften mittels kleiner oligonukleotidbasierter Verbindungen | |
TW200519089A (en) | Biaryl sulfonamides and methods for using same | |
PL1668001T3 (pl) | Podstawione heteroarylobenzofuranowe kwasy | |
TW200519100A (en) | Biaryl sulfonamides and methods for using same | |
WO2003046132A3 (en) | Antisense modulation of myd88 expression | |
MXPA05008360A (es) | Oligonucleotidos inmunomoduladores cortos. | |
WO2003053341A3 (en) | Antisense modulation of ship-1 expression | |
WO2003057843A8 (en) | Methods and materials for modulating trpc4 | |
WO2003052062A3 (en) | Antisense modulation of cd36l1 expression | |
TNSN05052A1 (en) | Immunostimulatory nucleic acids | |
WO2003057847A8 (en) | METHODS AND MATERIALS FOR MODULATING ENaC-BETA | |
DE60120410D1 (de) | Modulation der tetraspanin funktion | |
EP1496121A3 (de) | Modulierung der durch CpG-oligonukleotide verursachte Immunstimulierung durch positionsbedingte Veränderung von Nukleosiden | |
EP1448762A4 (de) | Antisense-modulation der expression des toll-ähnlichen rezeptors 4 erfindungsgebiet | |
WO2003105754A3 (en) | ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR B (VEGF-B) EXPRESSION | |
WO2003057898A8 (en) | Methods and materials for modulating p2x2 | |
WO2003053342A3 (en) | Antisense modulation of cd81 expression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |